Drug Could Significantly Reduce Oral Mucositis in Head and Neck Cancer

KRISTIE L. KAHL
Thursday, January 25, 2018
Oral mucositis is a common, often debilitating side effect of cancer treatments, in which epithelial cells that line the gastrointestinal tract are broken down, leaving the mucosal tissue open to ulceration or infection. It is a painful condition, causing the inability to eat which can also lead to nutritional problems, and an increased risk for infection as a result of open sores. There is a significant unmet treatment need for patients experiencing oral mucositis.

But there is hope on the horizon. A new drug, GC4419, being developed by Galera Therapeutics, shows promise in mitigating oral mucositis. It is currently being evaluated among patients with head and neck cancer who have severe cases of it.

“Seventy percent of those patients [with head and neck cancer] get what is called severe oral mucositis, and that has the immediate and deleterious effect of sores being painful, but it also interferes with eating, and it can cause treatment interruptions. And then there are more chronic effects that occur later on, like dry mouth, xerostomia, and others that can have longer term consequences,” Mel Sorensen, CEO of Galera Therapeutics, said in an interview with Oncology Nursing News.

Oral mucositis can lead to reduced quality of life, chemotherapy or radiation dose-limiting, and increased treatment costs from antibiotics or narcotics or additional or longer hospital stays.

GC4419 is a first-in-class, small molecule enzyme mimetic that converts superoxide to hydrogen peroxide and molecular oxygen. Sorensen explained that this conversion can be selective among patients being treated with radiation.

“In patients who are getting radiation for cancer treatment, the super oxide is created and it overwhelms the natural system. So, you get a build-up of super oxide in tissues,” he added.  “In fact, you get a selective build-up of super oxide tissues in normal tissues. What we can do with our compound, is because we convert it to hydrogen peroxide and the cancer cells are more sensitive to the hydrogen peroxide, there is a build-up of hydrogen peroxide in the cancer cells. So, that is where we get our selectivity.”

In the double blind, placebo-controlled phase 2a trial, researchers randomized 223 patients with head and neck cancer to receive either 30 mg or 90 mg of GC4419 or placebo by infusion on the days they received their radiation treatment. Patients were scheduled to receive seven weeks of radiation therapy plus cisplatin, therefore, the researchers aimed to determine the duration of severe oral mucositis they experienced in this timeframe.

Patients in the placebo arm endured having severe oral mucositis for an average of 19 days, whereas the group of patients who received the 90-mg dose of GC4419 only experienced the side effect for about a day and a half – a 92 percent reduction.

Severe oral mucositis occurred in 58 percent of the placebo arm, but in only 40 percent of patients who received the 30-mg dose and 37 percent of those who received 90 mg.

In addition, patients treated with GC4419 experienced longer delays in the time to onset of oral mucositis, and fewer grade 4 events occurred. The agent was also tolerated and the frequency of treatment-related side effects was comparable across all treatment arms in the trial.

“There are three things about this study that are very important for demonstrating that our technology works,” said Sorensen. “The first is we had a very robust result, highly statistically significant and clinically relevant in the primary endpoint. The second is that all of the secondary endpoints pointed in the same direction, that they were consistent with the primary endpoint. And third is that the intermediate dose, 30 mg, was also intermediate in results between the two arms.”

Sorensen noted these trial results show promise in reducing additional radiation-related toxicities. “This was a demonstration that we could not only selectively reduce the toxicity of radiation, but also preserve the activity of the chemoradiation, in other words, not reduce that against the cancer.”

Therefore, Galera Therapeutics intends to further investigate GC4419 as an agent to treat and reduce, and go after the cancer itself, as well as the side effects, Sorensen said.

“We want to make sure that our plan and our discussion with the FDA results in the most efficient way to get this to patients because after all everything we do is theoretical until we can actually get it to patients, which is what we want to do,” he added.

 

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.